Change in Director / Key Managerial Personnel
Nature of change: Appointment of Senior Management Personnel
Name and DIN: Dr. Sridevi Khambhampaty (DIN not disclosed in the data)
Effective date and tenure: Effective July 22, 2026. Term of appointment not specified.
Brief profile and qualifications: Dr. Sridevi is an accomplished biopharmaceutical leader with over two decades of experience spanning Biologics R&D, Quality, and Business leadership. Most recently, she served as the CEO of Shilpa Biologics. Prior to this, she held senior leadership roles at Syngene International and Intas Biopharma. In her previous stint at Dr Reddy's, she led teams in Product Development and Quality Control at Biologics. She holds a PhD in Biological Sciences from NCBS (TIFR) and completed postdoctoral research at Stanford University School of Medicine.
Confirmation of eligibility: Not explicitly mentioned in the data.
Relationship with other directors: Not applicable as per the disclosure.
Previous KMP: The position of Global Head of Biologics appears to be a new appointment rather than a replacement, as it was not listed in the previous Senior Management Personnel roster provided in Annexure A1.
Key Financial or Operational Approvals
Appointment of Independent Registered Public Accounting Firm: The Board of Directors approved the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm of the Company for the purpose of auditing the financial statements to be included in the Company's Annual Report on Form 20-F and reviewing the interim financial statements to be filed with the U.S. Securities and Exchange Commission on Form 6-K.
This appointment aligns with the company's previous communication dated May 12, 2026, regarding the appointment of Deloitte Haskins & Sells, LLP as Statutory Auditors for a term of five consecutive years commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to shareholder approval.
Firm Details: Deloitte Haskins & Sells LLP is a Limited Liability Partnership registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018). The registered office is at One International Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.
Strategic or Business Context
The appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics signifies the company's strategic focus on strengthening its biologics division. Her extensive experience in biologics development strategy, regulatory sciences, and cross-functional leadership, along with her previous experience at Dr. Reddy's, indicates a commitment to expanding the company's biosimilars portfolio and building high-performing teams in this specialized area.
Any Other Material Information
Regulatory Compliance: The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Updated Senior Management List: The appointment adds Dr. Sridevi Khambhampaty as the 14th member of the Senior Management Personnel, reporting structure not specified.